Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty

Trial Profile

Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2013

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Fracture; Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2013 New trial record
    • 01 Apr 2013 Preliminary results published in the Journal of Arthroplasty.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top